• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medical device unit can’t overcome JNJ recall woes

Medical device unit can’t overcome JNJ recall woes

January 25, 2011 By MassDevice staff

JNJ logo

How do you spell relief?

For Johnson & Johnson (NYSE:JNJ), which has been battered for months by a series of recalls involving its over-the-counter pharma products (including Rolaids), it’s not D-E-S.

Cordis Corp., the stent-making operation of the New Brunswick, N.J.-based medical products giant said sales were down 10 percent during the fourth quarter of 2010. The unit posted Q4 sales of $629 million, compared to $697 million during the same period last year. For the full year, Cordis pulled in $2.5 billion, a 4.7 percent slide from $2.7 billion in 2009.

Drug-eluting stent sales, including Cordis’s flagship Cypher device, fell across the board during the quarter. Worldwide DES sales were $134 million, down 38 percent from $223 million during the 2009 fourth quarter.

The news wasn’t much better for the full year. J&J’s DES sales plunged 31 percent to $627 million, down from $919 million during 2009.

Company officials said the slumping DES sales were the result of “continued market and competitive pressures.” Cordis jostles for market position with other device mammoths including the vascular division of Abbott (NYSE:ABT), Medtronic Inc. (NYSE:MDT) and Boston Scientific Corp. (NYSE:BSX).

Despite Cordis’ DES woes, the medical device unit was the lone bright spot for JNJ during the quarter. Overall, the unit posted $6.32 billion in sales, a 1.6 percent increase from the $6.30 billion during the same period last year.

The device segment posted $23.6 0 billion in sales during 2010, up 4 percent from 2009’s $23.57 billion. More than half of the division’s revenues came from overseas last year.

The top-line uptick was primarily driven by its two Ethicon-branded divisions. Ethicon itself saw surgical care product sales jump 9 percent to $4.5 billion; J&J’s Ethicon Endo-Surgery division drove sales up 6 percent to $4.75 billion.

DePuy, Johnson & Johnson’s orthopedics brand, also performed well in 2010. Sales were up about 4 percent to $5.58 billion, about 4 percent over 2009’s haul of $5.37 billion.

But DePuy also cost J&J some $922 million in legal costs and settlements related to the DePuy ASR hip implant recall in August 2010.

JNJ’s constellation of recall woes took a big chunk out of overall fourth-quarter sales, which were down 5.5 percent to $15.6 billion, from $16.5 billion in Q4 2009. For the full year, sales were flat at $61.6 billion, down half a tick from $61.9 billion in 2009.

The bottom line was off about 12 percent during the fourth quarter, to $1.9 billion, or 70 cents per share, compared to $2.2 billion, or 79 cents a share, during Q4 2009.

Chairman and CEO William Wheldon warned investors on a conference that more recalls could come for its over-the-counter unit, as an internal audit unwinds.

“Most of it is behind of us,” Wheldon said. “But there could still be a little ahead of us.”

The company issued earnings guidance for full-year 2011 of $4.80 to $4.90 per share, lower than analysts’ consensus of $4.97. JNJ shares were down about 2 percent in mid-day trading.

Filed Under: Business/Financial News, MassDevice Earnings Roundup, News Well Tagged With: Johnson and Johnson

More recent news

  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech
  • China reportedly launches country’s first invasive BCI trial
  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy